DE60213230T2 - Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit - Google Patents

Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit Download PDF

Info

Publication number
DE60213230T2
DE60213230T2 DE60213230T DE60213230T DE60213230T2 DE 60213230 T2 DE60213230 T2 DE 60213230T2 DE 60213230 T DE60213230 T DE 60213230T DE 60213230 T DE60213230 T DE 60213230T DE 60213230 T2 DE60213230 T2 DE 60213230T2
Authority
DE
Germany
Prior art keywords
eye
dry eye
inhibitors
compositions
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213230T
Other languages
German (de)
English (en)
Other versions
DE60213230D1 (de
Inventor
A. Daniel Arlington GAMACHE
M. John Burleson YANNI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of DE60213230D1 publication Critical patent/DE60213230D1/de
Application granted granted Critical
Publication of DE60213230T2 publication Critical patent/DE60213230T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60213230T 2001-05-21 2002-05-17 Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit Expired - Lifetime DE60213230T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29249501P 2001-05-21 2001-05-21
US292495P 2001-05-21
PCT/US2002/015859 WO2002095704A1 (en) 2001-05-21 2002-05-17 Use of nf-kappa-b inhibitors to treat dry eye disorders

Publications (2)

Publication Number Publication Date
DE60213230D1 DE60213230D1 (de) 2006-08-31
DE60213230T2 true DE60213230T2 (de) 2006-11-23

Family

ID=23124921

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213230T Expired - Lifetime DE60213230T2 (de) 2001-05-21 2002-05-17 Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit

Country Status (17)

Country Link
US (1) US6696453B2 (https=)
EP (1) EP1393277B1 (https=)
JP (1) JP2004527578A (https=)
CN (1) CN1509462A (https=)
AT (1) ATE333273T1 (https=)
AU (1) AU2002309963B2 (https=)
BR (1) BR0209965A (https=)
CA (1) CA2447883A1 (https=)
CY (1) CY1105220T1 (https=)
DE (1) DE60213230T2 (https=)
DK (1) DK1393277T3 (https=)
ES (1) ES2263785T3 (https=)
MX (1) MXPA03010632A (https=)
PL (1) PL367286A1 (https=)
PT (1) PT1393277E (https=)
WO (1) WO2002095704A1 (https=)
ZA (1) ZA200308769B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2497977A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
CN112263672A (zh) * 2020-11-04 2021-01-26 武汉益承生物科技有限公司 一种p55pik抑制剂在制备干眼治疗药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US4996209A (en) 1988-06-20 1991-02-26 Alcon Laboratories, Inc. Ophthalmic antiinflammatory compositions comprising S(+)-flurbiprofen
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
DE69115990T2 (de) 1990-05-29 1996-05-30 Ocular Res Of Bonton Inc Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
DE4028906A1 (de) 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
DE4140184C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
CA2133966C (en) 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5686436A (en) 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
FR2718441B1 (fr) * 1994-04-07 1996-06-28 Bioxytech Nouveaux composés de structure benzisoséléna-zoline et -zine, leur procédé de préparation et leurs applications thérapeutiques.
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
RU2172630C2 (ru) 1995-08-14 2001-08-27 Оксиджен, Инк. Комбинация в виде пищевой добавки или лекарства и способ лечения человека и животных с ее использованием (варианты)
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6100299A (en) 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US6046185A (en) 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
WO2000003705A1 (en) 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
CA2359561A1 (en) 1999-01-20 2000-07-27 Shiro Akinaga Proteasome inhibitors
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
BR0010134A (pt) 1999-04-27 2002-01-15 Novartis Ag Uso de derivados de ácido 2,4-diamino-3-hidroxicarboxìlico como inibidores de proteassoma

Also Published As

Publication number Publication date
PL367286A1 (en) 2005-02-21
ATE333273T1 (de) 2006-08-15
CA2447883A1 (en) 2002-11-28
ZA200308769B (en) 2005-01-26
PT1393277E (pt) 2006-09-29
JP2004527578A (ja) 2004-09-09
ES2263785T3 (es) 2006-12-16
US6696453B2 (en) 2004-02-24
WO2002095704A8 (en) 2003-09-18
EP1393277A1 (en) 2004-03-03
EP1393277B1 (en) 2006-07-19
DK1393277T3 (da) 2006-10-30
US20030008854A1 (en) 2003-01-09
DE60213230D1 (de) 2006-08-31
WO2002095704A9 (en) 2003-02-27
MXPA03010632A (es) 2004-03-09
CY1105220T1 (el) 2010-03-03
CN1509462A (zh) 2004-06-30
AU2002309963B2 (en) 2007-03-01
BR0209965A (pt) 2004-04-06
WO2002095704A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
DE3310079C2 (https=)
EP1455803B2 (de) Verwendung von panthenol und/oder panthothensäure und hyaluronsäure/und oder hyaluronat zur herstellung einer pharmazeutischen zusammensetzung zur ophtalmologischen anwendung
DE3851152T2 (de) Cyclosporin-augenmittel.
DE68902649T2 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
US7026296B2 (en) Methods of treating dry eye disorders
DE69513902T2 (de) Augenpräparat zur Verwendung in künstlicher Tränenflüssigkeit
DE69423782T2 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
DE69713032T2 (de) Verwendung von SCF für Behandlung der Cornea
DE69730476T2 (de) Albumin als aktiver Bestandteil zur Behandlung von Bindehaut- und Hornhautverletzungen und von trockenen Augen
DE2708152A1 (de) Pharmazeutisches traegermaterial und dessen verwendung
DE60008143T2 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
EP1453523B1 (de) Heparin-haltiges ophthalmikum
Bartlett et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis
KR20070004750A (ko) 건안증 치료에 있어서의 로테프레드놀　에타보네이트의용도
DE69208941T2 (de) Augenpräparate mit verlängerter Freigabe
DE60218153T2 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE69033587T2 (de) Topische behandlung von blepharitis
DE60213230T2 (de) Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit
US6645994B1 (en) Method of treating dry eye disorders
DE10360425A1 (de) Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
EP0484581B1 (de) Verwendung von Thromboxan-A2-Antagonisten zur Verhinderung von degenerativen Vorgängen im penilen Gewebe
CN1239161C (zh) 可用于治疗干眼疾病的类固醇
AU2002309963A1 (en) Use of NF-KAPPA-B inhibitors to treat dry eye disorders
WO1997030724A1 (de) Rt-pa zur prävention des nachstars nach kataraktoperation
US20040209888A1 (en) Methods of treating dry eye disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition